


ETCTN Trials by Disease/Treatment Area: Gynecologic Cancer



## ETCTN Gynecologic Cancer Trials (Open as of 6/9/2025)

Protocol Number	Phase	Protocol Title
<b>10324</b>	I/Ib	A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with M3814 in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
<b>10401</b>	0	A Phase 0 window-of-opportunity pharmacodynamic trial of triapine (NSC# 663249) in uterine corpus serous adenocarcinoma
<b>10422</b>	I/Ib	A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer
<b>10355</b>	I	A phase I study of DS-8201a in combination with olaparib in HER2-expressing malignancies
<b>10433</b>	I/Ib	Phase I/Ib trial evaluating the safety and efficacy of BET inhibitor, ZEN003694 with PD-1 inhibitor, nivolumab with or without CTLA-4 inhibitor, ipilimumab in solid tumors
<b>10597</b>	I	A Phase 1 trial of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers